Supernus Pharmaceuticals Inc (SUPN)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 69,331 | 75,054 | 93,120 | 203,434 | 288,640 |
| Short-term investments | US$ in thousands | 384,281 | 179,820 | 368,214 | 136,246 | 133,893 |
| Receivables | US$ in thousands | 142,077 | 144,155 | 165,497 | 148,932 | 140,877 |
| Total current liabilities | US$ in thousands | 292,397 | 290,196 | 687,958 | 315,379 | 245,108 |
| Quick ratio | 2.04 | 1.38 | 0.91 | 1.55 | 2.30 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($69,331K
+ $384,281K
+ $142,077K)
÷ $292,397K
= 2.04
The quick ratio of Supernus Pharmaceuticals Inc has fluctuated over the past five years. Starting at 2.30 in December 31, 2020, the ratio decreased to 1.55 by December 31, 2021. Subsequently, it further declined to 0.91 by December 31, 2022, indicating potentially lower liquidity and a reduced ability to cover short-term obligations with its most liquid assets. However, there was an improvement in the quick ratio by December 31, 2023, when it rose to 1.38, suggesting an enhanced ability to meet short-term liabilities. Furthermore, by December 31, 2024, the quick ratio increased to 2.04, surpassing the initial ratio in 2020 and possibly indicating improved liquidity and financial health. Overall, the trend in the quick ratio of Supernus Pharmaceuticals Inc demonstrates variability but also shows signs of recovery and sound liquidity management in recent years.
Peer comparison
Dec 31, 2024